InflaRx NV(IFRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 14.75% | Shs Outstand | 147.4M | Perf Week | 12.09% |
| Market Cap | 0.25B | Forward P/E | - | EPS next Y | -29.74% | Insider Trans | - | Shs Float | 125.6M | Perf Month | -4.72% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -0.06 | Inst Own | 58.55% | Short Float | 10.13% | Perf Quarter | 0.88% |
| Income | - | P/S | - | EPS this Y | 58.8% | Inst Trans | 53.71% | Short Ratio | 16.62 | Perf Half Y | -17.15% |
| Sales | - | P/B | 1.51 | EPS next 5Y | 14.79% | ROA | - | Short Interest | 12.73M | Perf YTD | 69.8% |
| Book/sh | 1.13 | P/C | 1.39 | EPS past 3/5Y | -2.98% 11.77% | ROE | - | 52W High | -41.84% ($2.95) | Perf Year | 24.28% |
| Cash/sh | 1.23 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 114.8% ($0.80) | Perf 3Y | -0.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -40.62% | Gross Margin | - | Volatility(W/M) | 5.82% 7.4% | Perf 5Y | -59.55% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.22 | EPS Q/Q | 23.88% | Profit Margin | - | RSI (14) | 53.25 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.22 | Sales Q/Q | - | SMA20 | 9.38% ($1.57) | Beta | 2.38 | Target Price | $8.32 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/6 | SMA50 | -8.61% ($1.88) | Rel Volume | 0.4 | Prev Close | $1.73 |
| Employees | 65 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -56.63% -100% | SMA200 | 4.97% ($1.64) | Avg Volume(3M) | 0.77M | Price | $1.72 |
| IPO | 2017/11/8 | Option/Short | Yes/Yes | Trades | 1282 | Volume | 306,544 | Change | -0.87% |
🧬 InflaRx (IFRX) is a clinical-stage biotech company developing antibody and small-molecule therapies that target C5a in the complement immune pathway. Founded in Germany in 2007, it focuses on chronic inflammatory and autoimmune diseases and runs its pipeline around its lead candidate vilobelimab and the oral candidate INF904.
Over the past 1 year, roughly in the middle
42% below its 1-year high.
Traded less than usual. That is 40% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +58.8% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -59.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 58.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
LYTE Roundhill Photonics & Optics ETF <0.01% It ranks #283 of 594 in the industry
Based on market cap of $253M.
FAQ
What kind of company is IFRX?
IFRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IFRX?
The market cap of IFRX is approximately $253M, ranking 3,831 within its sector.
What is the 52-week high and low for IFRX?
IFRX has recorded a 52-week high of $2.95 and a low of $0.80.
